Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

BACKGROUND. Therapies targeting vascular endothelial growth factor (VEGF) are associated with hypertension, cardiotoxicity, and thromboembolic events. METHODS. All prospective phase I–III clinical trials published up to December 2008 of approved anti-VEGF therapies (bevacizumab, sunitinib, sorafenib...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Vaklavas, Christos, Lenihan, Daniel, Kurzrock, Razelle, Tsimberidou, Apostolia Maria
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2010
Ämnen:
Cancer Biology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227935/
https://ncbi.nlm.nih.gov/pubmed/20139170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0252
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk